DrugManagementForum.com

More Targeted Cancer Therapies Set to Become "Blockbusters"

This is a discussion on More Targeted Cancer Therapies Set to Become "Blockbusters" within the Other Clinical Pharmacy News forum, part of the Industry News and Updates category; Targeted cancer therapeutics have become best-selling products and are driving overall growth in the oncology pharmaceutical market. Medscape Medical ...


Go Back   DrugManagementForum.com > Industry News and Updates > Other Clinical Pharmacy News

Register Help Members List Mark Forums Read

Rate This Thread - More Targeted Cancer Therapies Set to Become "Blockbusters".

Only registered members can vote. To rate this thread register here.

Reply

 

Thread Tools
  #1 (permalink)  
Old 10-10-2008, 02:32 PM
automated news aggregator
 
Join Date: Jan 2008
Posts: 1,083
Default More Targeted Cancer Therapies Set to Become "Blockbusters"

Targeted cancer therapeutics have become best-selling products and are driving overall growth in the oncology pharmaceutical market.
Medscape Medical News

More...
Reply With Quote
Reply


Thread Tools
Display Modes


Similar Threads

Thread Thread Starter Forum Replies Last Post
Targeted Therapies Improve Outcomes in Renal Cancer and GIST, but Challenges Remain industry_news Other Clinical Pharmacy News 0 09-14-2008 08:19 AM
Technical Brief: Particle Beam Radiation Therapies for Cancer industry_news Comparative Effectiveness Updates 0 07-16-2008 12:25 PM
Technical Brief: Particle Beam Radiation Therapies for Cancer industry_news Comparative Effectiveness Updates 0 07-15-2008 07:16 PM
ALSO NOTED: Targeted Genetics buys Sirna's share of program; Indevus in $21M licensing deal;Atrium Innovations sells di industry_news Biotechnology News 0 04-07-2008 02:58 PM
Comparison of Therapies for Clinically Localized Prostate Cancer industry_news Comparative Effectiveness Updates 0 03-10-2008 04:01 PM


© 2008 DrugManagementForumpowered by
Informaceutica - Drug Management Information Company

All times are GMT -4. The time now is 12:37 AM.